Clinical trial · Observational
Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions
iBEAM-Based Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Superb Micro-vascular Imaging (SMI) based on the iBeam platform is used to evaluate the blood supply of solid tumors. Compared with color Doppler technology, the sensitivity, accuracy and consistency of the ability of SMI to display blood flow are evaluated. Thus, the investigators will use Superb-Microvascular imaging (SMI, Toshiba, Japan) for diagnosing hepatic lesions, which enable to detect slow micro vascular flow inside the tumor
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatic Lesion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Superb-Microvascular imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- hepatic lesion
- interventionNames
- Device: Superb-Microvascular imaging
Primary outcomes (1)
- measure
- diagnostic accuracy
- timeFrame
- 1 week preoperatively
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Visible hepatic lesion on US 2. Agree to participate in the study 3. Accessible follow-up imaging or pathological results Exclusion Criteria: 1\. Pregnant women
References
Publications (0)
Data not yet available